BK Medical appointed as sole agent for AMD's Prostate HistoScanning in UK

Advanced Medical Diagnostics SA (AMD), a privately held company committed to providing innovative computer-aided solutions (HistoScanning™) that can improve the diagnostic interpretation of ultrasound scans, today announced that it has appointed BK Medical UK Ltd as sole agent for Prostate HistoScanning™ in the UK.

HistoScanning™ is an innovative and proprietary tissue characterization technology used to differentiate, characterize, and visualize solid organ tissue types based on the analysis of backscattered ultrasound. It is designed to support physicians in diagnosis and treatment decisions.

Prostate HistoScanning™, available in Europe, may support the diagnosis and management of prostate cancer. HistoScanning™ products for breast, thyroid, and ovaries are in development.

Advanced Medical Diagnostics SA and BK Medical UK Ltd have been working closely together since the commercial launch of Prostate HistoScanning™ in November 2008. These systems have been placed in four major teaching hospitals in the UK, most recently at Guys Hospital and Charing Cross Hospital in London.

As agents, BK Medical Limited will be responsible for the day-to-day management of sales and for providing service support for UK customers.

Over the last 18 months, BK has been instrumental in placing over 20 Prostate HistoScanning™ systems alongside the BK Pro Focus and Pro Focus UltraView ultrasound systems in leading urology departments across Europe.

Toby Hamblin, VP Sales of AMD, commented, "BK Medical, with its strong base in ultrasound urology in the UK, is very well placed to help us realise the full potential of Prostate HistoScanning™ and to provide the NHS and private clinics alike with the service and support that they, and this exciting new technology, deserve. We are very pleased to have the support of BK Medical in this important market."

Geoff Pick, managing director, BK Medical UK Ltd, added, "Prostate HistoScanning™ is an important product for us here in the UK and will help us maintain our position at the forefront of innovation in urology ultrasound technology. We are delighted that we will be able to provide our customers with this important technology and look forward to providing HistoScanning™ customers with the same excellent level of service that our current ultrasound users enjoy."

HistoScanning™ has not yet received market clearance by the U.S. Food and Drug Administration for commercial use in the United States.